Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/UMEC/VI Dry Powder Inhaler for Cough Symptoms in Adult Asthma
jRCTs031210412Completed
- Sponsor
- GSK
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in asthma comparing FF/UMEC/VI 200/62.5/25 mcg once daily with Placebo once daily (2 arms). Primary endpoint: Mean change from baseline in cough symptoms score over Week 6. Started Jul 2022; status: completed.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate
03
Conditions
asthma
Beyond the preview
Go deeper on jRCTs031210412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210412.